Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019.
10.1097/CM9.0000000000002600
- VernacularTitle:Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019
- Author:
Jiangmei LIU
1
;
Weiping LIU
2
;
Lan MI
2
;
Cai CAI
3
;
Tiejun GONG
4
;
Jun MA
4
;
Lijun WANG
1
Author Information
1. Department of Vital Statistics and Death Surveillance National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
2. Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China.
3. Strategic Development Department, Beijing Institute of Survey and Mapping, Beijing Municipal Key Laboratory of Urban Spatial Information Engineering, Beijing 100038, China.
4. Department of Hematology & Oncology, Harbin Institute of Hematology and Oncology, Harbin, Heilongjiang 150010, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Male;
Female;
Adult;
Aged;
Global Burden of Disease;
Quality-Adjusted Life Years;
Multiple Myeloma/epidemiology*;
Global Health;
Incidence;
Prevalence;
Risk Factors;
China/epidemiology*
- From:
Chinese Medical Journal
2023;136(23):2834-2838
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:There is limited data to comprehensively evaluate the epidemiological characteristics of multiple myeloma (MM) in China; therefore, this study determined the characteristics of the disease burden of MM at national and provincial levels in China.
METHODS:The burden of MM, including incidence, mortality, prevalence, and disability-adjusted life years (DALYs), with a 95% uncertainty interval (UI), was determined in China following the general analytical strategy used in the Global Burden of Disease, Injuries, and Risk Factors Study 2019. The trends in the burden of MM from 1990 to 2019 were also evaluated.
RESULTS:There were an estimated 347.45 thousand DALYs with an age-standardized DALY rate of 17.05 (95% UI, 12.31-20.77) per 100,000 in 2019. The estimated number of incident case and deaths of MM were 18,793 and 13,421, with age-standardized incidence and mortality rates of 0.93 (95% UI, 0.67-1.15) and 0.67 (95% UI, 0.50-0.82) per 100,000, respectively. The age-specific DALY rates per 100,000 increased to more than 10.00 in the 40 to 44 years age group reaching a peak (93.82) in the 70 to 74 years age group. Males had a higher burden than females, with approximately 1.5- to 2.0-fold sex difference in age-specific DALY rates in all age groups. From 1990 to 2019, the DALYs of MM increased 134%, from 148,479 in 1990 to 347,453 in 2019.
CONCLUSION:The burden of MM has doubled over the last three decades, which highlights the need to establish effective disease prevention and control strategies at both the national and provincial levels.
